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Introduction: Pneumocystis pneumonia (PcP) has classically been described as a 
serious complication in patients infected with the human immunodeficiency virus 
(HIV). However, the emerging number of conditions associated with 
immunosuppression has led to its appearance in other patient populations, such as 
those receiving chronic corticosteroid therapy, those with hematological or solid 
malignancies, transplant recipients and those who receive immunomodulatory or 
biological therapy. 
Areas covered: This article reviews the most recent publications on PcP in the HIV-
infected and HIV-uninfected population, focusing on epidemiology, diagnostic, therapy 
and prevention.  The data discussed here were mainly obtained from a non-systematic 
review using Medline and references from relevant articles including randomized 
clinical trials, meta-analyses, observational studies and clinical reviews. Eligible studies 
were selected in two stages: sequential examination of title and abstract, followed by 
full text. 
Expert opinion:  Widespread use of antiretroviral and prophylactic therapy in HIV-
infected patients has decreased the incidence of PcP in this population. However, the 
growing incidence of Pneumocystis infection in the HIV-uninfected population suggests 
the need for new global epidemiological studies in order to identify the true scale of 
the disease in this population. These data would allow us to improve diagnosis, 
therapeutic strategies, and clinical management. It is very important that both patients 
and physicians realize that HIV-uninfected patients are at risk of PcP and that rapid 
diagnosis and early initiation of treatment are associated with better prognosis. 
Currently, in-hospital mortality rates are very high:  15% for HIV-infected patients and 
50% in some HIV-uninfected patients. Therefore, adequate preventive measures 














• Pneumocystis is prevalent in the lungs of immunocompetent individuals, 
suggesting that asymptomatic healthy adult carriers provide a reservoir for 
Pneumocystis infection.  
• In HIV-infected patients the risk for PcP increases exponentially when the CD4+ 
cell count is below 200 cells/µl. Patients on ART who develop PcP typically have 
low CD4+ cell levels due to poor adherence to ART or possible resistance to 
ART. 
• There is a growing incidence of Pneumocystis infection in the HIV-uninfected 
population due to the emerging number of conditions associated with 
immunosuppression. These include hematological malignances, solid tumors, 
solid-organ transplantation, autoimmune diseases, steroids therapy, 
immunosuppressive or biological therapy. 
• There is strong evidence of the presence of Pneumocystis in the air of areas 
where infected patients reside and of a transmission through interpersonal 
contacts. It is reasonable to isolate infected patients until respiratory symptoms 
resolution or discharge from hospital; when patients need to be moved a mask 















In the last decade the number of immunocompromised patients has increased 
globally[1,2]. Patients with immunosuppression show an increased risk of pulmonary 
infectious complications like Pneumocystis pneumonia (PcP). Indeed, the risk of PcP 
and other fungal infections is elevated in patients with human immunodeficiency virus 
(HIV) infection, chronic corticosteroid use, hematological or solid malignancies, organ 
transplantation and immunomodulatory or biological therapy, although the data 
regarding prevalence come from a small number of patients in single-center or single-
country studies [3–5]. (Figure 1).  
Pneumocystis jirovecii is probably transmitted via environment aerosols from infected 
patients or colonized individuals[6]. The global incidence of PcP is unclear due to its 
non-specific symptoms, the difficulty to obtain good respiratory samples and to 
perform microbiological diagnosis. Delayed or missing PcP diagnosis may compromise 
the early initiation of an adequate therapy, thus increasing the risk of poor outcomes.  
Because of the widespread use of antiretroviral and prophylactic therapy in HIV-
infected patients, the incidence and mortality of PcP has fallen in recent decades[7]. 
However, several studies still report high mortality rates among HIV-uninfected 
patients probably due to the greater intensity of the inflammatory response, the 
acuteness of symptoms, the more frequent progression to respiratory failure requiring 
tracheal intubation [8], and  also the influence of different management practices[9–
13]. 
The aim of this review is to present and discuss recent advances in our understanding 
of PcP in HIV-infected and HIV-uninfected patients. We focus principally on its 












that this information will help to identify patients at risk and will help in the diagnosis 




Pneumocystis jirovecii is an obligate fungal organism with high tropism for the alveolar 
epithelium of the lung. Generally, it attaches to cells without invading them, thus 
showing a parasitic behavior[9]. Trophic and cystic forms have been identified in its life 
cycle, with trophic forms predominating over the cystic ones during lung 
infections[14]. Unfortunately, the inability to culture Pneumocystis outside the lung 
limits the complete comprehension of its life cycle [15,16]. Pneumocystis rarely causes 
disseminated infections, although some cases have been reported in patients with 
AIDS[17,18].  
Infection generally occurs in immunosuppressed patients due to the acquisition of a 
new infection rather than the reactivation of a latent one. In a rat model of prior PcP 
episodes, animals did not present reactivation of Pneumocystis infection when 
immune suppression was induced, unless they have been exposed to other rats with 
active infection[19]. Interestingly, the latency model of infection in humans by 
Wakefield et al.[15] (which used 47 bronchoalveolar lavage samples from 16 HIV-
infected patients) showed that after a PcP episode in HIV-infected patients 
asymptomatic carriage of Pneumocystis did not last longer than 9.5 months. 
Pneumocystis transmission has been understood to be interindividual. It has been 












although no established reservoir has been identified so far and several possible routes 
of transmission have been considered. Nosocomial interhuman transmission is one 
possibility, with Rabodonirina et al.[24] demonstrating the pathogen transmission 
between HIV-infected patients with PcP and hospitalized renal transplant recipients. 
Yazaki et al.[25] investigated the environmental exposure as a possible route of 
Pneumocystis transmission following an outbreak of PcP in renal transplant recipients. 
The authors detected in outpatients consulting rooms P. jirovecii  deoxyribonucleic 
acid (DNA) with the same genotypes as in clinical samples obtained two months 
earlier. Finally, data on Pneumocystis colonization in immunocompetent[26–29] or 
physiologically immunosuppressed individuals (e.g., pregnant woman)[30] have led to 
the hypothesis that these groups may act as contagious sources for susceptible 
persons, making them possible reservoirs in the community[14]. 
Mother-to-infant transmission of P. jirovecii has also been described. In a pilot study of 
33 third-trimester, pregnant, asymptomatic healthy women (median age 26 years) and 
28 controls (healthy women within 15 days of a menstrual period; median age 28 
years). Vargas et al.[30] detected P. jirovecii DNA in deep nasal swab samples in five 
(16%) of the 33 pregnant women but in none (0%) of the controls. Thus explaining why 
primary Pneumocystis infection can be acquired early in life (i.e., through vertical 
transmission). Montes-Cano et al.[31] analyzed placentas and lungs of 20 fetuses at 28 
± 8 weeks of gestation. P. jirovecii was observed in lung tissue samples from 7 (35%) 
fetuses, thus confirming the possibility of a trans placental transmission in humans. 
Interestingly, the study by Rojas et al.[32]. that investigated the prevalence of P. 
jirovecii colonization in 128 preterm infants and its possible association with medical 












studied. The authors suggested that P. jirovecii colonization could be a risk factor for 
ARDS in preterm infants. 
3. Focusing on colonization  
Colonization or subclinical infection with P. jirovecii is defined as the isolation of P. 
jirovecii in respiratory samples in patients with no specific symptoms or history of PcP. 
Interstitial pneumonia is the major clinical manifestation in patients with active 
infection for P. jirovecii [6]. 
Several studies have identified possible colonization in both HIV-infected and HIV-
uninfected patients[6,14,26,28,29]. Colonization influences interindividual 
transmission of the pathogen, appearance of lung inflammation and damage, 
progression of the disease and development of resistance. 
3.1. Colonization in immunocompetent individuals 
A prospective Spanish study [33] was designed to determine whether P. jirovecii can be 
detected in the normal, healthy population. It investigated oropharyngeal wash 
samples from 50 persons who had not been exposed to patients in a hospital 
environment within the year before the study, or who had not been diagnosed with, or 
were not suspected to have, chronic lung disease, neoplasm, or immunosuppression of 
any cause. P. jirovecii DNA was present in 24% of cases. All carriers were 
asymptomatic, HIV-uninfected and had normal total lymphocyte and CD4+ cell counts. 
Similarly,  in a study of the detection of P. jirovecci DNA in oropharyngeal wash and 
nasal swab samples from 110 immunocompetent older adults (>65 years), Vargas et 
al.[34] reported that P. jirovecii DNA was detected in 13% of oropharyngeal wash 












wash and nasal swab samples together, the rate of detection rose to 22%. 
Interestingly, the authors reported that none of the participants developed PcP within 
1 year of study completion.  As the above studies reported, Pneumocystis is frequently 
detected in the respiratory tract of immunocompetent individuals, suggesting that 
asymptomatic healthy adult carriers provide a reservoir for Pneumocystis 
infection[33,34].   
3.2. Colonization in patients with Chronic Lung Diseases 
Several studies have reported Pneumocystis colonization in individuals with chronic 
lung diseases (chronic obstructive pulmonary disease [COPD], cystic fibrosis, chronic 
bronchitis, and asthma)[35,36]. Some of these studies have also found an association 
between lung disease progression and colonization with Pneumocystis. In a study of 
Pneumocystis colonization rates in lung tissue obtained during lung resection or 
transplantation in smokers with a range of airway obstruction severity and in a control 
group with lung diseases other than COPD, Morris et al.[35] found Pneumocystis 
colonization in 36.7% of patients with very severe COPD and in 5.3% of smokers with 
normal lung function or less severe COPD. Colonized individuals presented more 
severe airway obstruction (median FEV (1) = 21% predicted versus 62% in non-
colonized subjects, p = 0.006). The authors found that the Global Health Initiative on 
Obstructive Lung Diseases (GOLD) GOLD IV classification[37] was the strongest 
predictor of Pneumocystis colonization (odds ratio: 7.3, 95% confidence interval = 2.4 
to 22.4, p < 0.001) and was independent of smoking history. 
 An interesting study on the distribution of Pneumocystis colonization in the lungs of 












lung tissue of 19 patients with COPD and without HIV infection who underwent lung 
transplantation. Pneumocystis colonization was detected in 42% of patients with 
advanced COPD. Colonization was more frequent in the lower and middle lobes than in 
upper lobes. According to the authors, these differences in the distribution of 
colonization may be due to the lower sensitivity of Pneumocystis detection in the 
upper lobes of COPD patients because the disease has already become end-stage in 
these areas of the lung, or because these areas have lower tissue content. The authors 
also tentatively attributed the relative propensity for lower lobe colonization to the 
greater ventilation in the lower regions of the lung than in the upper regions. 
The authors suggested that the use of a single sample from an individual might 
underestimate the prevalence of Pneumocystis colonization[36]. 
3.3. Colonization in patients with Immunosuppression 
There is significant variability regarding the rate of Pneumocystis colonization in 
patients with HIV, with studies reporting rates between 6% and 68%[6,38–41]. This 
variation reflects differences in the study populations, biological samples and 
microbiological tests. Gutierrez et al.[42] analyzed the prevalence of P. jiroveci 
colonization in oropharyngeal wash samples in a cohort of 20 young HIV-infected 
patients and found colonization in 40% of the population; after 50 weeks of follow-up, 
only one colonized patient with advanced immunosuppression developed PcP.   
Mekinian et al.[43] analyzed Pneumocystis colonization in 67 patients with systemic 
autoimmune diseases and 28 controls (healthy subjects). None of the selected patients 
had respiratory or general signs of current Pneumocystis infection but the authors 












evidence of colonization, compared with 7% (n=2) in the control group. The authors 
also analyzed the risk factors for colonization in patients with systemic autoimmune 
diseases, finding that male gender was the only risk factor. However, after a new 
analysis with nested models the authors were able to attribute the difference in the P. 
jirovecii colonization to the higher level of induced immunosuppression in the male 
patients, as suggested by lymphocyte counts and corticosteroid volume. 
4. Infection  
4.1. Risk Factors in HIV-infected patients 
Incidence of PcP infection in HIV-infected patients fell substantially with the 
widespread use of active antiretroviral therapy (ART), especially in developing 
countries[44]. Most cases of PcP now occur in patients who have undiagnosed HIV 
infection, who are not receiving ART or who are not adhering to ART at the time of PcP 
diagnosis, or in cases of sub-optimal immune recovery [45–47]. The risk for PcP 
increases exponentially when the CD4+ cell count is below 200 cells/µl[17]. Patients on 
ART who develop PcP typically have low CD4+ cell levels due to poor adherence to ART 
or possible resistance to ART[46]. When in patients on ART the CD4+ cell count (> 200 
cells/µl) increases, the risk for PcP decreases sufficiently to safely discontinue both 
primary and secondary prophylaxis[17,48].  
Recent global estimates report that approximately more than 400,000 cases of PcP in 
patients with acquired immunodeficiency syndrome (AIDS) occur each year[49,50]. The 
case fatality rate is approximately 15% in patients with AIDS, despite optimal 
treatment [51]. Interestingly, a systematic review and meta-analysis of the prevalence 












showed a fall in the prevalence of PcP from 28% to 9% after 2005. 
The overall annual incidence of PcP in HIV-infected adults ranges from 0.9 to 5.4 cases 
per 1000 person-years [5,53,54]. In the United States and Canada, a recent study of 16 
large cohorts of HIV-infected patients showed a fall in the incidence of PcP from 0.92 
events/100 person-years in 2000–2003 to 0.39 events/100 person-years in 2008–2010 
[9]. Similarly, a Spanish study [45] of 136 PcP cases indicated a significant reduction in 
the annual incidence of PcP from 13.4 to 3.3 cases per 1000 HIV-infected patients per 
year during the period between 2000 and 2013. However, the proportion of patients 
with PcP before a diagnosis of HIV also rose from 48% in 2000 to 67% in 2013, 
confirming that PcP remains an important health problem in patients with HIV[45]. 
Certainly, the use of ART has influenced the incidence of PcP. Reporting trends in AIDS-
defining opportunistic illnesses over a 25 year period (1987–2012) in Brazil, Coelho et 
al.[56] found a significant reduction in the incidence of PcP from 87.2 to 2.84 
cases/1000 person-years between the periods 1987–1990 and 2009–2012. The 
authors observed that the use of ART increased over these years, with almost 80% of 
patients receiving ART in the latter period. 
The mortality rate associated with PcP in HIV-infected patients is reported to be 15%, 
ranging from 4% to 32% on the basis of the population studied, the underlying chronic 
diseases, the immunological status and the precocity of diagnosis [7,51]. Several  risk 
factors have been related to mortality in HIV-infected patients: older age, subsequent 
episodes of PcP, low haemoglobin level and low basal PaO2 at hospital admission, 
pulmonary Kaposi sarcoma and pre-existing comorbidities[57,58]. However, recent 












4.2. Risk Factors in HIV-uninfected patients 
PcP is emerging as an important infectious disease in HIV-uninfected persons [4,13]. It 
is estimated that the annual incidence of PcP in this population exceeds 100,000 cases 
globally, that the case fatality rate is about 50% and that there are more than 50,000 
related deaths[49].  The conditions most frequently associated with an increased risk 
of PcP are: 
*Hematological malignancies (especially leukemia and lymphomas): in this population 
risk factors related to PcP include the use of corticosteroids, monoclonal antibody 
therapy, or T-cell dysfunction related to underlying disease or therapy. 
*Solid tumors (e.g., brain, breast, lung, and renal): it is reported that the main risk 
factors in this population are the high-dose chemotherapy and marrow 
transplantation, and the prolonged use of corticosteroid therapy.  
*Solid-organ transplantation: in this population, the main risk for Pneumocystis 
infection is CD4+ lymphocytopenia. 
*Autoimmune diseases (e.g., rheumatoid arthritis, inflammatory bowel diseases and 
ankylosing spondylitis): in this population, low CD4+ cell count and the use of anti-
TNFα, rituximab or cyclophosphamide may increase the risk. 
*Patients receiving steroid, immunosuppressive or biological therapy (anti-tumor 
necrosis factor [TNF], anti-interleukin 6, anti-interleukin 1, anti-cd52, or anti-CD20) are 
also at increased risk [60–62]. 
Hematologic populations at highest risk of PcP are those with acute lymphoblastic 












transplantation (HSCT)[63]. The nationwide study in the UK by Maini et al.[5] analyzed 
data from 2258 cases of PcP over a decade (2000–2010) and showed an increase in the 
incidence of PcP, particularly in patients who had an hematologic malignancy or who 
had undergone transplantation. The number of cases rose from 157 in 2000 to 352 in 
2010 (a mean annual increase of 9%). The authors attribute this increase to the 
improvements in diagnostic methods over the study period. With regard to the 
increased transmission of the P. jirovecii organism between susceptible persons, the 
authors suggest that the levels of exposure of susceptible persons to infectious 
persons may rise as a result of changes in the delivery of health care. Other possible 
reasons mentioned are the increase in the number of potentially vulnerable patients 
who did not receive appropriate prophylactic therapy, and an increase in the use of 
potent immunosuppressant agents in several medic l conditions. 
In 2014 an interesting French study on the incidence of PcP was published by Fillatre et 
al.[64]]. The study was carried out between 1990 and 2010 and 293 cases of PcP were 
detected, 154 (52%) of which in HIV-uninfected patients. The main underlying 
conditions associated with PcP were hematological malignancies (32%), solid tumors 
(18%), inflammatory diseases (15%), solid-organ transplantation (12%) and vasculitis 
(10%) (Figure 1). The authors grouped the risk and the incidence of PcP into three 
categories according to the underlying diseases or conditions: 
• Low risk (incidence <25 cases/100,000/patient-years): inflammatory diseases, 
Hodgkin lymphoma, and other solid tumors. 
• Intermediate risk (incidence 25–45 cases/100,000/patient-years): Waldenström 












• High risk (incidence >45 cases/100,000/patient-years): polyarteritis nodosa, 
granulomatosis with polyangiitis, polymyositis/dermatopolymyositis, acute 
leukemia, chronic lymphocytic leukemia, and non-Hodgkin lymphoma. 
Recently, a French study [65] proposed a score to predict the risk of Pneumocystis 
infection in patients with hematological malignancies and acute respiratory failure 
(ARF) requiring ICU admission. Variables included in the score were age (<50 [1 point]; 
50-70 [-1.5 points]; >70 [-2.5 points]), lymphoproliferative disease (2 points), anti-
Pneumocystis prophylaxis (1 point), respiratory symptom duration (<3 days [0 point]; 
3 to 5 days [3 points]; >5 days [3 points]), shock (-1.5 points), chest radiograph pattern 
(2.5 points) and pleural effusion (-2 points).  The cut-off score for the definition of 
pneumocystis was three points. The score showed a specificity of 88% and a negative 
predictive value of 97% of for PcP. The authors expect this score to accelerate the 
initiation of anti-PcP therapy. 
Mortality remains higher in HIV-uninfected patients than in HIV-infected patients 
(40%–60% [62,64] and 5%–15% [7,66] respectively), probably due to the higher 
inflammatory response, the acute presentation of symptoms, the rapid progression to 
respiratory failure with the need for invasive mechanical ventilation [8] and the 
different management practices. Mortality in intensive care unit (ICU) is very high for 
HIV-uninfected patients with PcP. A study of 82 patients with PcP admitted to ICU 
showed a mortality rate of 76%, with the main risk factors being increased age, raised 
white blood cell counts and the presence of a pneumomediastinum [12].  












Table 1 summarizes the clinical presentation, radiographic features and outcomes of 
PcP in HIV-infected and HIV-uninfected patients. HIV-infected patients typically show a 
sub-acute onset of the infection, longer symptoms duration (3 weeks), low-grade fever 
with progressive dyspnea and less severe course with a mortality rate of 
15%[46,51,67]. HIV-uninfected individuals, by contrast, typically have a rapid onset, 
fast progression to respiratory failure, shorter symptoms duration (4-7 days) , are more 
likely to require ICU admission and fulminant course with a mortality rate of 30%- 60%. 
The different clinical presentation is not associated with the pulmonary fungal load; in 
fact, it seems to be related to pneumonia severity and the degree of lung 
inflammation. Limper et al. found that patients with PcP and AIDS have more 
Pneumocystis organisms and fewer neutrophils in the lung than immunocompromised 
patients with PcP without AIDS (with the exception of organ transplant patients), and 
that inflammation in the lower respiratory tract (as measured by the number and 
percentage of lavage neutrophils and not by microorganism number) is associated with 
greater impairment of gas exchange and lower patient survival in PcP with and without 
AIDS [68]. 
Roux et al. [51] reported clear differences in the clinical features of PcP between 223 
patients with AIDS and  321 patients with other immunosuppressive disorders (non-
AIDS patients). Patients without AIDS had significantly shorter median times from 
symptom onset to presentation (5 days, compared with 21 days for patients with AIDS; 
p < 0.001), hypoxemia was more severe; ICU admission was more common (50% vs. 
35%; p = 0.001), and both non-invasive (16% vs. 8%; p = 0.005) , invasive (30% vs. 11%; 
p = 0.001) mechanical ventilation were required more often and lower in-hospital 












published study from Portugal that assessed the differences between 75 HIV and 54 
non-HIV patients with PcP. The authors reported that the clinical presentation in non-
HIV patients was more tenuous (respiratory complaints: 67% vs 37%, p = 0.002), but 
with worse outcomes than in HIV-infected patients (in-hospital mortality: 10% vs 20%, 
p = 0.002)[69]. 
6. ART and the Immune Reconstitution Inflammatory Syndrome in PcP 
The immune reconstitution inflammatory syndrome in PcP (PcP-IRIS) is an exaggerated 
pulmonary immune reaction occurring in HIV-infected patients after ART starting in 
response to Pneumocystis infection, mediated by  the immune system recovery [70]. 
PcP-IRIS has been associated with high morbidity and ICU admission but mortality 
rates are very low; the reason for this lower mortality could be the fact that the 
patients received corticosteroids, which have immunomodulatory properties and may 
regulate the inflammatory storm of IRIS, or that these patients are on PcP therapy 
which reduces the Pneumocystis load [71–74]. The timing of PcP-IRIS presentation in 
relation to ART initiation dictates its further definition: “paradoxical IRIS” refers to a 
worsening of symptoms secondary to Pneumocystis infection after ART starting and 
treatment for PcP, whereas “unmasked IRIS” refers to Pneumocystis infection that is 
undiagnosed before ART. Although the onset of PcP-IRIS is variable, it usually occurs 
within 3 months of ART starting [70]. 
The true incidence of PcP-IRIS remains unclear because most data have come from 
case reports[71,75]. A retrospective study in the USA by Achenbach et al.[76] on 
patients suffering opportunistic infections after ART starting reported that IRIS 












Early initiation of ART does not affect the incidence of PcP-IRIS[77]. Also, according to 
clinical trial data for the optimal timing of ART initiation in AIDS-related opportunistic 
infections (OI), it is recommended to start ART therapy within two weeks of OI 
treatment initiation when there is co-infection with PcP [78]. 
Clinically, PcP-IRIS presents as a worsening of existing PcP or an unmasking of PcP[72]. 
Most patients display an inflammatory response upon starting therapy directed against 
Pneumocystis, which is tempered by treatment with corticosteroids; however, some 
patients develop a worsening of pulmonary disease after starting ART, presenting 
fever, dyspnea and worsening hypoxia. The common radiological manifestations in PcP 
IRIS are the presence of ground glass opacities, but in some cases atypical radiological 
manifestations such as consolidations, organization pneumonia, and absence of 
effusion and nodes have been reported [70].  Currently, the consensus is to continue 
with ART due to the possibility that HIV replication progresses, but to start specific 
treatments for any co-infection[17].  
7. Radiographic features 
HIV-infected patients generally present bilateral interstitial and alveolar infiltrates in 
perihilar areas (Figure 2, a, b). Conversely, HIV-uninfected patients generally show 
diffuse lung infiltrates and evident consolidations, with few cases presenting 
pulmonary cysts or pneumatoceles (Figure 2, c, d). Radiographic chest patterns are 
not–specific in general. Several studies have described the role of the High Resolution 
Computed Tomography (HRCT) of the chest in the diagnosis of PcP in HIV-infected and 












The study by Fuji et al.[79] described the clinical features of 34 episodes of PcP in 32 
HIV-infected patients. HRCT of the lung showed  ground-glass opacities (GGO) sparing 
the lung periphery in 41% of episodes, or displaying a mosaic pattern (29%), or being 
nearly homogeneous (24%), GGO associated with air-space consolidation (21%), 
associated with cystic formation (21%), associated with linear-reticular opacities (18%), 
patchily and irregularly distributed (15%), associated with solitary or multiple nodules 
(9%) and associated with parenchymal cavity lesions (6%). 
In HIV-uninfected patients consolidations and GGO have been reported more 
frequently [80]. Interestingly, the study by Mu et al.[83] investigated the relationship 
between radiological stages (early: early normal or nearly normal on chest x-ray or 
bilateral diffuse GGO on chest CT; mild: mild bilateral infiltrates on chest x-ray or 
bilateral diffuse GGO and patchy consolidations on chest CT; late: late bilateral 
consolidations on chest x-ray or bilateral predominant consolidations on chest CT) and 
PcP prognoses in 105 HIV-uninfected PcP immunocompromised patients. According to 
the chest HRCT, 40 cases were at early stage, showing bilateral diffuse GGO, and the 
case fatality rate (CFR) was 20.0% (P> 0.05); 34 cases were at mid stage, showing 
bilateral diffuse GGO and patchy consolidations, and the CFR was 47.1% (P> 0.05); 
finally, 10 cases were at late stage, showing predominant consolidations in bilateral 
lung fields, and the CFR was 80.0% (P< 0.05The authors described other radiographic 
findings such as bilateral diffuse GGO with mosaic signs and consolidations, pleural 
effusions, small nodules, aerothorax, pneumomediastinum, pneumohypoderma, cystic 
lesions and thickened lobular septa. 
8. Microbiological Diagnosis 












However, in a recent study by Schildgen et al.[84] it was successfully cultured and 
propagated from a positive BAL sample. Propagation was possible in CuFi-8 cells, 
derived from the bronchus of a patient with cystic fibrosis, and EpiAirway cells, derived 
from human tracheal/bronchial epithelial cells. Unfortunately, no other study  has 
been able to  replicate this method of propagation[16].  
The most frequently used respiratory samples for PcP diagnosis in HIV-infected 
patients are induced sputum (less invasive but with low sensitivity) or BAL (higher 
diagnostic yield). It is known that the immunosuppression profile influences the 
Pneumocystis load in the infection[51,68], HIV-uninfected patients have a lower 
burden of organisms and so may present false negative results. PcP diagnosis in HIV-
uninfected patients requires invasive samples such as BAL or lung biopsies. Other 
noninvasive samples such as spontaneous sputum, nasopharyngeal aspirate (NA), and 
oropharyngeal washing (OW) may be useful in the diagnosis of pneumocystis. Of 
course, their sensibility raises to75% when analysed together with molecular tests such 
as PCR compared to microscopy[85–87]. 
8.1. Microscopy 
The gold standard for the microbiological diagnosis of P. jirovecii is the microscopic 
observation of the microorganism in respiratory samples. Staining methods include 
Grocott-Gomori methenamine silver, toluidine blue-O, calcofluor white, Giemsa stain, 
and Diff-Quik. Cystic forms are more often observed with the first three methods, 
whereas trophic forms with the last two methods [88].  
In HIV-infected patients with higher microorganism burden, rapid detection by indirect 












and specificity in BAL (99% and 100% respectively) or induced sputum (50% and 100% 
respectively) using other staining methods as a gold standard. This assay facilitates the 
identification of both cystic and trophic forms [89]. However, in HIV-uninfected 
patients with a low microorganism burden, microscopy of BAL is less sensitive; these 
patients could benefit from the use of molecular techniques[90].  
Figure 3 shows a representative microscopic observation of a typical BAL sample. 
8.2. Molecular Diagnosis 
Conventional PCR and real-time PCR assays can detect P. jirovecii DNA in various 
samples, including induced sputum, oral washings, nasopharyngeal aspirates, nasal 
swabs, BAL, and lung tissue these techniques  provide a rapid diagnosis of PcP and help 
in the initiation of prompt therapy [91]. Molecular assays can also quantify 
Pneumocystis in clinical samples, and may help in monitoring the effectiveness of 
antifungal therapy and in differentiating colonization from infection[92]. The 
established method involves the detection of the mitochondrial large-subunit 
ribosomal RNA of P. jirovecii [93], both in HIV-infected and HIV-uninfected individuals. 
The main limitation of molecular techniques is the lack of standardization. Further 
studies are needed before these assays can be incorporated into routine clinical 
practice. However, molecular techniques improve the diagnostic yield for PcP, provide 
rapid diagnosis and have been applied to minimally invasive clinical specimens. 
Figure 4 shows a tentative algorithm for the microbiological diagnosis of PcP. 
8.3. Differentiation between Colonization and Active Infection 
Several studies have tried to discriminate between colonization and active infection. 












patterns and microbiological results (microscopic examination and quantitative PCR 
(qPCR) performed on the BAL fluids) from 1003 patients with pneumonia. The authors 
divided the BAL sample into four groups: a) definite PcP (microscopic demonstration of 
trophic or cyst forms); b) probable PcP (clinical PcP including outcome after anti-
Pneumocystis therapy and radiological pattern supporting the diagnosis of PcP and 
positive qPCR but negative microscopic observation of Pneumocystis forms; c) 
Pneumocystis colonization (absence of clinical and radiological evidence of PcP but 
positive qPCR and negative microscopic observation of Pneumocystis forms; d) lack of 
Pneumocystis infection (absence of clinical data supporting the diagnosis of PcP and 
absence of positive qPCR or a positive microscopy observation). The rate of 
colonization was 4% among 180 HIV-infected patients and 12% among 823 HIV-
uninfected patients. The authors suggested using a qPCR cut-off of 1.5 × 104 copies/mL 
(100% sensitivity and specificity) to distinguish colonization from infection in HIV-
infected patients. For HIV-uninfected patients, cut-off values of 2.87 × 104 copies/mL 
and 3.39 × 104 copies/mL obtained 100% specificity and sensitivity respectively. HIV-
infected patients developed PcP with a lower fungal burden compared to HIV-
uninfected patients.  
More recently, Fauchier et al. [38] evaluated the cycle threshold (CT) values (the 
number of PCR cycles after which the reaction is considered positive) obtained by 
qPCR, which are correlated with the fungal burden in the sample, in order to 
differentiate between colonization and PcP on  respiratory samples (sputum, induced 
sputum, bronchoalveolar lavage [BAL] fluid) from immunocompromised patients with 
respiratory symptoms. Considering the receiver operating characteristic curve (ROC), 












• a CT value of 32 discriminated between colonization and pneumonia with 72% 
of sensitivity and 75% of specificity (area under the ROC curve [AUC], 0.88); 
• in HIV-infected patients, a CT value of 27 excluded colonization with a 
sensitivity of 74% and a specificity of 100% (AUC, 0.90);  
• in HIV-uninfected patients, a CT value of 35 excluded colonization with a 
sensitivity of 80% and a specificity of 60% (AUC, 0.72).  
Although these data suggest the utility of qPCR cut-offs to distinguish colonization 
from infection, they cannot be applied universally. Clinicians should always consider 
the fungal load variability due to patients characteristics (HIV-infected, HIV-uninfected 
or degree of immunosuppression), specimen type (invasive or non-invasive) and 
sample quality.  
9.  Biochemical Diagnosis 
9.1. Serum detection of (1-3)-β-D-Glucan 
The main component of the cell wall in P. jirovecii cysts is the (1-3)-β-D-glucan (BG), 
this polysaccharide is released into the circulation during Pneumocystis infection in 
detectable quantities. The study by Son et al.[94] that compared blood levels of BG in 
patients with PcP, patients with other diseases (like candidemia, chronic disseminated 
candidiasis, invasive aspergillosis, mucormycosis and tuberculosis) and in healthy 
volunteers found that at a cut-off value > 31.25 pg/mL, which is highly sensitive for PcP 
versus tuberculosis plus healthy volunteers at the expense of specificity, BG had a 
sensitivity of 92% and a specificity of 55%. More recently, Lahmer et al.[95] 
investigated the usefulness of serum BG in mechanically ventilated HIV-uninfected 












overall sensitivity of 92%, and specificity of 84% for PcP diagnosis, with a high negative 
predictive value. Interestingly, a bivariate meta-analysis and systematic review 
published in 2015 analyzed 33 studies on the role of serum BG in the diagnosis of PcP 
in HIV-infected and HIV-uninfected patients. The authors found that in HIV-infected 
patients a negative serum BG was sufficient for ruling out PcP, as confirmed in other 
studies[96,97]. Conversely, in HIV-uninfected patients results of serum BG should be 
interpreted in parallel with clinical and radiological findings[98].  
Although these studies reported that the detection of this polysaccharide in the serum 
has a specificity of 96% and a sensitivity of 87% [99], it is not a specific biomarker of 
PcP. Its use is limited by the lack of a standardized detection method, the fact that 
extraneous factors (e.g., immunoglobulins) may cause false-positive results and the 
fact that high values cannot distinguish between different fungal infections [100]. For 
these reasons, the use of BG is recommended only in combination with other 
diagnostic tests. 
Figure 4 shows a tentative algorithm for the diagnosis of PcP. 
9.2. S-adenosyl methionine and other biomarkers 
S-adenosyl methionine (SAM) is a molecule that P. jirovecii cannot synthesize, but 
necessary for its metabolism. It is an essential intermediate for protein and nucleic 
acid methylation, folate metabolism, and polyamine synthesis. P. jirovecii therefore 
requires exogenous SAM and in a study of rats it was observed that plasma SAM 
concentration was inversely correlated with the lung P. jirovecii count [101]. 
Subsequent testing in human PcP also revealed low plasma SAM concentrations during 












Recently, the study by Esteves et al.[104] investigated the useful of four serologic 
biomarkers [(Krebs von den Lungen-6 antigen (KL-6), BG, lactate dehydrogenase (LDH) 
and SAM ]for the diagnosis of PcP. The authors found that BG was the most promising 
biomarker, followed by KL-6, LDH and SAM. The combination of BG and KL-6 showed 
the highest accuracy, with 94.3% sensitivity and 89.6% specificity.  The authors 
recommended their use both in HIV-infected and HIV-uninfected patients. Conversely, 
despite SAM concentration was slightly decreased in PcP cases, the sensitivity and 
specificity analysis demonstrated that SAM failed to discriminate between patients 
with and without PcP, showing low diagnostic accuracy. 
In clinical practice, we recommend the use of biomarkers in association with other 
specific diagnostic tests for Pneumocystis that compleme t the interpretation of 
clinical and radiological data. Although biomarkers and molecular assays are important 
tools for identifying PcP, the lack of standardized methods makes their 
implementation difficult in routine clinical practice. 
10. Therapy 
Table 2 summarizes the main recommendations for PcP treatment in HIV-infected and 
HIV-uninfected patients.  Furthermore, details regarding PcP therapy (first line and 
alternative treatments) and prophylaxis in HIV-infected patients have been provided 
by Huang et al. [105] in a recently published review covering the main areas of the 
topic.  
Some points regarding additional or alternative therapies in PcP are worthy of 
importance: 












infected patients with moderate-to-severe PcP due to its benefits in terms of 
survival [106]. However, adjunctive corticosteroid therapy is not indicated in 
HIV-infected patients with mild-to-moderate PcP. 
• Due to the conflicting results regarding their benefit, glucocorticoids are not 
recommended in HIV-uninfected patients with PcP. According to current 
guidelines, the decision to add corticosteroids in HIV-uninfected patients with 
PcP and respiratory failure should be made on a case by case basis[107]. 
• Folinic acid supplements are contraindicated  in HIV-infected patients with PcP 
because of the increased risk of treatment failure and death [17,108].  
• Clinical experience regarding the use of caspofungin in severe PcP is limited, 
controversial and based on case reports of severe PcP successfully treated with 
a combination of low-dose cotrimoxazole and caspofungin in different 
populations[109–112]. These data suggest the need for future randomized 
clinical trials. 
• Cases of treatment failure with cotrimoxazole and dapsone have been 
associated with mutations in the DHPS gene of P. jirovecii [113–117]. However, 
research results are unclear and there is only limited information regarding 
these mutations and their association with outcomes and therapy. Moreover, 
prophylaxis with sulfamethoxazole may be a risk factor for DHPS mutations 
[118,119]. 
• Corticosteroids are recommended for the treatment of paradoxical or 
unmasked PcP-IRIS [70]. 
•  The use of clindamycin and primaquine as salvage therapy is not currently 












However, they may be recommended in cases in which the first and alternative 
therapies cannot be administered or are not tolerated[17]. 
 
11. Prevention of exposure and disease 
Although there is evidence of the presence of P. jirovecii in the air in areas where 
infected patients reside  and of transmission through interpersonal contact[21,22], and 
although contact between severely immunocompromised patients and patients with 
confirmed Pneumocystis infection should be avoided, there are insufficient data to 
support the practice of isolation of patients with PcP in routine clinical practice[17]. 
11.1.- Primary and secondary prophylaxis 
Table 3 summarizes the primary and secondary prophylaxis in HIV-infected and HIV-
uninfected patients. 
• Primary prophylaxis should be discontinued in HIV-infected patients when the 
CD4 count increases from <200 cell/mm3 to ≥ 200 cell/mm3 for at least 3 
months in response to ART therapy or when the CD4 count is 100–200 
cell/mm3 and the viral load suppressed[120]. 
• Secondary prophylaxis should be discontinued in HIV-infected patients when 
the CD4 count increases from <200 cell/mm3 to ≥200 cell/mm3 for at least 3 
months in response to ART and HIV-viral load is undetectable over 3 months. 
[121]. 
• There is no consensus about secondary prophylaxis in HIV-uninfected patients. 
However, it is recommended to continue secondary prophylaxis until 
















Although the incidence of PcP is decreasing in patients with HIV, principally because of 
ART introduction, several major concerns persist in different areas. Notably, there are 
many patients with unknown HIV infection at the time of PcP diagnosis; many patients 
do not receive ART or are non-compliant with the therapy; finally there is a rising 
incidence of patients who are immunocompromised for reasons other than HIV 
infection. These concerns are compounded by difficulties with PcP diagnosis.  
13. Expert opinion 
 
During recent years, the scientific community has made significant progress in the 
epidemiology, diagnosis and management of PcP. However, many questions remain 
unresolved regarding our understanding of the pathophysiology of Pneumocystis 
infection, especially in relation to the microorganism-host interaction. The reservoir of 
Pneumocystis infection has not yet been identified and the mechanism of transmission 
and infection are not entirely clear; nor has an ideal diagnostic strategy  been defined. 
For this reason, it is important that the research topics listed below be explored in the 
coming years.  
First, epidemiological studies are needed to investigate the global burden of PcP and 
its attributable mortality. Due to the differences in the study populations, biological 
samples, and microbiological tests, observational studies should be carried out to 












patients. Moreover, prospective studies are required to identify risk factors for PcP, 
mostly in the “new” group of HIV-uninfected patients, and to recognize patients who 
would truly benefit from prophylaxis. 
The main issue regarding P. jirovecii diagnosis is the difficulty of isolating or culturing 
the pathogen with conventional microbiological methods. Studies on accelerated 
diagnosis, through rapid and non-invasive molecular techniques, would make it 
possible to differentiate P. jirovecii colonization from infection, and thus allow prompt 
initiation of targeted therapies. A comparison between current treatment strategy and 
an approach integrating clinical stratification with old and new biomarkers could 
provide important strategic insights. Finally, the role of caspofungin in severe PcP 
should be assessed in randomized clinical trials.  
13.1 Five-year view 
The widespread use of antiretroviral and prophylactic therapy in HIV-infected patients 
has reduced the incidence of PcP in this population. However, the growing incidence of 
Pneumocystis infection in HIV-uninfected patients (those receiving chronic 
corticosteroids, those with hematological or solid malignancies, transplant recipients, 
and those receiving immunomodulatory or biological therapy) suggests the need for 
new studies to define the true scale of the disease. Currently, in-hospital mortality 
rates are very high: 15% for HIV-infected patients and 50% in some HIV-uninfected 
patients. Early identification of patients at risk for PcP and the development of 
standardized microbiological diagnostic methods for early Pneumocystis detection 
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Table 1. Clinical manifestations, radiographic features and outcomes of Pneumocystis 
pneumonia in HIV-infected and HIV-uninfected patients 
 
HIV-infected patients HIV-uninfected patients 
Sub-acute onset Rapid onset 
Longer symptoms duration (3 weeks) Shorter symptom duration (4–7 days) 
Low-grade fever with progressive dyspnea High grade fever and rapid progression to 
respiratory failure 
Bilateral interstitial and alveolar infiltrates 
involving perihilar areas 
Consolidation with ground-glass opacities 
10-20% require ICU admission  Approximately 50% require ICU 
admission 
Less severe course with a mortality rate of 
15% (range 10%–20%) 
Fulminant course with a mortality rate of 
30%–60% 
Prognostic factors: 
Acute respiratory failure (PaO2 <60 mmHg, 
A-aO2 gradient) at admission, delay in ICU 
admission, need of mechanical ventilation, 
marked chest radiographic abnormalities, 
pneumothorax, low serum albumin; low 
hemoglobin, high LDH, high APACHE II score, 
increased age, injection drug use, previous 
PCP, pulmonary KS, and coinfections and 
comorbidities. 
Prognostic factors: 
Respiratory failure, pre-existing lung 
disease, pneumothorax, lymphopenia, 
increased BUN, high lactate 
dehydrogenase, low serum albumin, 
adjunctive steroid therapy, longer time 
from onset of symptoms to diagnosis. 
















HIV-infected patients with 
moderate-to-severe PCP 
*First line:  TMP-SMX: 15–20 mg/kg (TMP); 75–100 mg/kg (SMX) per day, in 3 or 4 divided doses for 21 days 
(The dose must be adjusted if there is abnormal renal function). 
* Alternatives: 
• Pentamidine 4 mg/kg IV once daily (may be reduced to 3 mg/kg IV once daily if toxicities arise). 
• Primaquine 30 mg (base) once daily + (Clindamycin 600/6h or 900 mg/8) or (450 mg/ 6h or 600 mg/8h). 
 
Adjunctive corticosteroid: start as early as possible if PaO2 <70 mmHg in room air or alveolar-arterial O2 gradient 
≥35 mmHg.  
Doses recommended: days 1–5: 40mg (oral) twice daily; days 6–10:40mg (oral) daily; days 11–15/20:20 mg (oral) 
daily.  











mild-to-moderate PCP * Alternatives:  
• Dapsone 100mg daily + TMP 15mg /kg/day, divided in 3 doses (oral) 
• Primaquine 30 mg (base) once daily + (Clindamycin 600/8h or 450 mg/ 6h) (oral) 
• Atovaquone 750 mg twice daily with food (oral) 
Adjunctive therapy with corticosteroids is not indicated 
HIV-uninfected patients: 
haematological 





*First line: TMP-SMX: 15–20 mg/kg (TMP); 75–100 mg/kg (SMX) per day, in 3 or 4 divided doses for ≥14 days.  
*Alternatives: 
• Pentamidine 4 mg/kg/day (iv). Primaquine + clindamycin 30 mg/day (oral) + 600 mg × 3/day (iv/oral). 
Atovaquone 750 mg in 2 or 3 doses per day (oral).  
 
Adjunctive therapy with corticosteroids (on a case-by-case basis) 













Table 3. Prophylaxis of PCP 
 
Primary prophylaxis 
  HIV-infected patients 
Initiate: if CD4 count < 200 cells/μL, CD4 percentage < 14%, oral thrush or relevant concomitant 
immunosuppression 
Stop: if CD4 count > 200 cells/μL over 3 months or CD4 count 100-200 cells/μL and HIV-VL 
undetectable over 3 months 
First line Dose 
Trimethoprim/sulfamethoxazole 
 
1 single-strength tablet (80 mg/400 mg) daily or 
1 double-strength tablet (160 mg/800 mg) daily. 
Second line  
Dapsone 1 x 100 mg/day p.o. 
Atovaquone 1 x 1500 mg/day p.o. (with food) 
Pentamidine aerosols 300 mg in 6 mL sterile water,1 inhalation/month 
HIV-uninfected patients 
First line Dose 
 
Trimethoprim/sulfamethoxazole 
1 single-strength tablet (80 mg/400 mg) daily or 
1 double-strength tablet (160 mg/800 mg) daily. 
Second line  
Dapsone 2 x 50 mg/day p.o. 
Atovaquone 1 x 1500 mg/day p.o. (with food) 
Pentamidine aerosols 300 mg in 6 mL of sterile water, 1 inhalation/month 
Secondary prophylaxis 
HIV-infected patients 




1 single-strength tablet (80 mg/400 mg) daily or 
1 double-strength tablet (160 mg/800 mg) daily. 
 
Atovaquone 1 x 1500 mg/day p.o. (with food) 













No general consensus: continuation of the secondary prophylaxis is recommended until the end of 
the immunosuppression condition. 
 
  
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
 
  
 
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
  
 
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
  
 
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
 
 
